Axitinib reimbursement conditions

Axitinib is a prescription drug, combined with avelumab, used for the first-line treatment of patients with advanced renal cell carcinoma (RCC) . In combination with pembrolizumab, it is used for the first-line treatment of patients with advanced renal cancer. As a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one previous systemic therapy.

Axitinib(Axitinib)Reimbursement conditions are limited to renal cell carcinoma. For details, please consult the relevant local departments. Axitinib is a second-generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumor growth, and metastasis. It is reported to exhibit 50-450 times greater potency than first-generation VEGFR inhibitors. Axitinib is an indazole derivative. It is commonly marketed under the trade name Inlyta and is available in oral dosage forms.

Aaxitinib mainly undergoes liver metabolism. CYP3A4 and CYP3A5 are the major liver enzymes, while CYP1A2, CYP2C19 and UGT1A1 are minor. The half-life of acetinib is 2.5 to 6.1 hours. The average clearance rate of axatinib is 38 liters/hours. Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism and may increase the serum concentration of axitinib. Avoid Hypericum perforatum. This herb induces CYP3A4 metabolism, which may decrease axitinib serum concentrations. There are generic drugs in Bangladesh. The retail price of Bangladesh Beacon Pharmaceutical is about 1,800 yuan for 5 mg and 60 tablets. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.